CD19-CAR T-cell therapy induces deep tissue depletion of B cells
Ann Rheum Dis 2024;0:1–8 DOI 10.1136/ard-2024-226142
Tur et al. demonstrated that CD19-targeting CAR T-cell therapy results in the depletion of B cells within deep tissues. The study highlights significant reductions in pathogenic B-cell populations, particularly in autoimmune diseases, after CD19-CAR T-cell administration.
This study focused on the efficacy of CD19-CAR T-cell therapy in depleting B cells, which is crucial for treating autoimmune diseases. It also aimed to characterise the long-term impact of B-cell depletion across various tissue compartments.
Keywords:
